$251.42
Value $42.7B
IQV and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$251.42
Value $42.7B
$265.93
Value $641B
IQVIA (IQV) has a market value of $42.7B and Johnson & Johnson (JNJ) $641B. Over the last year, with dividends, IQV moved +15.7% and JNJ +36.0%. The P/E is 30.6 for IQV and 39.8 for JNJ. Dividend yield: IQV none, JNJ 1.99%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
IQV$42.7B
JNJ$641B
JNJ is 15 times IQV
Revenue, 12 months
IQV$17.3B
JNJ$99.3B
JNJ is 5.7 times IQV
Net income, 12 months
IQV$1.4B
JNJ$16.1B
JNJ is 12 times IQV
Operating margin
IQV12.8%
JNJ–
ROIC
IQV8.4%
JNJ12.4%
4.0 points apart
P/E
IQV30.6
JNJ39.8
JNJ is 1.3 times IQV
Dividend yield
IQV0.0%
JNJ2.0%
2.0 points apart
5-year return
IQV-5.7%
JNJ+88.3%
94.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
IQV-5.7%
JNJ+88.3%
| Period | IQVWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +15.7%Price +15.7% | +36.0%Price +33.0% |
| 3 years since November 17, 2023 | +22.8%+7.1% a yearPrice +22.8% | +93.4%+24.6% a yearPrice +77.6% |
| 5 years since November 18, 2021 | -5.7%-1.2% a yearPrice -5.7% | +88.3%+13.5% a yearPrice +63.8% |
| 10 years since November 21, 2016 | +214.2%+12.1% a yearPrice +214.2% | +201.4%+11.7% a yearPrice +131.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
IQVIQVIAJNJJohnson & Johnson
| Price | $251.42 | $265.93 |
|---|---|---|
| Market value | $42.7B | $641B |
| Enterprise value (EV) | $56.3B | $668B |
| P/E | 30.6 | 39.8 |
| P/E, 5-year median | 31.7 | 21.9 |
| P/B | 6.4 | 7.9 |
| EV/EBIT | 25.4 | 37.7 |
| Free cash flow yield | 4.9% | 3.2% |
| Revenue, 12 months | $17.3B | $99.3B |
|---|---|---|
| Net income, 12 months | $1.4B | $16.1B |
| Free cash flow, 12 months | $2.1B | $20.6B |
| Earnings per share, 12 months | $8.22 | $6.59 |
| Revenue growth, year on year | 5.9% | 6.1% |
| Revenue growth a year, past | +7.5%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | +40.5%over 5 years | +14.9%over 5 years |
| Gross margin | 33.1% | 67.6% |
|---|---|---|
| Operating margin | 12.8% | – |
| Net margin | 8.1% | 16.2% |
| ROIC | 8.4% | 12.4% |
| ROE | 22.0% | 19.7% |
| Cash | $2.4B | $17.2B |
|---|---|---|
| Total debt | $16.3B | $44.7B |
| Net debt / EBITDA | 4.1 | 1.1 |
| Interest cover | 2.8× | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 2.9% | 0.9% |
| Shareholder yield | 2.9% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($641B) is about 15.0 times IQVIA ($42.7B), at today's prices.
Since November 21, 2016, IQV's price moved +214.2% and JNJ's +131.3%. With dividends: IQV +214.2% (+12.1% a year), JNJ +201.4% (+11.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for IQVIA and 1.99% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 30.6 for IQV and 39.8 for JNJ. The median of the last five years was 31.7 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 8.1% for IQVIA and 16.2% for Johnson & Johnson, and the operating margin 12.8% and –. Revenue was $17.3B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.